Inhibikase Therapeutics, Inc.

IKT Nasdaq CIK: 0001750149

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
Mailing Address 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DE, 19801
Phone (302) 295-3800
Fiscal Year End 1231
EIN 263407249

Financial Overview

FY2025

$8.30M
Total Liabilities
$178.80M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 7, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
10-K Annual financial report March 26, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
4 Insider stock transaction report February 24, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 17, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 13, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • Strategic pivot to the high-growth Pulmonary Arterial Hypertension (PAH) market via the acquisition of CorHepta Pharmaceuticals.
  • Advancement of lead drug candidate IKT-001 into a pivotal Phase 3 'IMPROVE-PAH' clinical trial.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.